The phaseI,II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with locally-advanced pancreatic cancer
Phase 1
- Conditions
- locally-advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000016630
- Lead Sponsor
- Hiroshima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(1)severe allegy for medicine (2)Patients with other malignant disease within 5 years (3)Patients with active infection (4)Patients with severe neuropathy(>Grade2) (5)Patients with ileus (6)Patients with interstitial pneumonia (7)Patients with uncontrallable ascites or pleural fluid (8)Patients with uncontrallable diabetes (9)Patients with uncontrallable heart disease (10)Patients with pregnant or possibly pregnant (14)Patients who have judged not suitable for this study by doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase I: incidence of adverse enent which apply for discontinuance criteria Phase II: 2 year survival rate, median survival time
- Secondary Outcome Measures
Name Time Method